keyword
MENU ▼
Read by QxMD icon Read
search

lung cancer,radiotherapy

keyword
https://www.readbyqxmd.com/read/27914779/what-do-radiation-oncologists-require-for-future-advancements-in-lung-sbrt
#1
REVIEW
Umberto Ricardi, Serena Badellino, Andrea Riccardo Filippi
Stereotactic Body Radiotherapy (SBRT) is a well established therapeutic option for patients affected with peripheral early stage non-small cell lung cancer (NSCLC), given the positive clinical evidence accumulated so far on its efficacy and safety. SBRT is regarded as the best choice for inoperable patients, and could also be offered as an alternative to surgery to selected operable patients. More recently, its use for lung metastases progressively increased, and SBRT is now regarded as a low toxic and highly effective local therapy for lung oligometastases from different primary tumors, especially colorectal cancer...
November 30, 2016: Physica Medica: PM
https://www.readbyqxmd.com/read/27914680/comparison-of-toxicity-and-outcome-in-advanced-stage-non-small-cell-lung-cancer-patients-treated-with-intensity-modulated-chemo-radiotherapy-using-imrt-or-vmat
#2
Robin Wijsman, Frank Dankers, Esther G C Troost, Aswin L Hoffmann, Erik H F M van der Heijden, Lioe-Fee de Geus-Oei, Johan Bussink
Retrospective evaluation of 188 advanced stage non-small cell lung cancer patients treated with IMRT or VMAT revealed a limited increase of moderate to severe acute esophageal toxicity after VMAT. Acute pulmonary toxicity and severe late toxicity were low. Overall survival did not differ between the IMRT and VMAT groups.
November 30, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/27913498/long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
#3
Flora E van Leeuwen, Andrea K Ng
Long-term survivors of Hodgkin lymphoma (HL) experience several late adverse effects of treatment, with second malignant neoplasms (SMNs) and cardiovascular diseases (CVDs) being the leading causes of death in these patients. Other late effects have also been identified, such as pulmonary dysfunction, endocrinopathies (thyroid dysfunction, infertility), neck muscle atrophy, and persistent fatigue. HL survivors have two- to fourfold increased risks to develop SMNs and CVD compared with the general population...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27912893/-perioperative-therapies-in-surgical-non-n2%C3%A2-non-small-cell-lung-cancer
#4
REVIEW
Anne-Marie Ruppert, Armelle Lavolé, Jalal Assouad, Jacques Cadranel, Marie Wislez
Platinum-based perioperative chemotherapy is actually the standard of care in stage II-IIIa non-small cell lung cancer (NSCLC). A benefit may also be seen in stage IB NSCLC with tumors of more than 4cm of diameter. Perioperative chemotherapy improves 5-year survival of 4 to 15%. This benefit is mainly proved by postoperative chemotherapy trials. Nevertheless, preoperative chemotherapy has advantages: a better tolerance, an estimation of tumor chemosensibility, without an increased postoperative morbimortality...
November 29, 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27912764/sbrt-for-centrally-localized-nsclc-what-is-too-central
#5
J Roesch, C Panje, F Sterzing, F Mantel, U Nestle, N Andratschke, M Guckenberger
PURPOSE: Current guidelines recommend stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer (NSCLC) in medically inoperable patients. There are excellent outcome and toxicity data for SBRT of peripheral lung tumors. However, the discussion on SBRT for centrally located tumors is controversial. This study evaluated current clinical practice regarding SBRT of centrally located lung tumors, to identify common fractionation schedules and commonly accepted contraindications for SBRT...
December 3, 2016: Radiation Oncology
https://www.readbyqxmd.com/read/27910826/enhancing-radiotherapy-for-lung-cancer-using-immunoadjuvants-delivered-in-situ-from-new-design-radiotherapy-biomaterials-a-preclinical-study
#6
Yao Hao, Sayeda Yasmin-Karim, Michele Moreau, Neeharika Sinha, Erno Sajo, Wilfred Ngwa
Studies show that radiotherapy of a primary tumor in combination with immunoadjuvants (IA) can result in increased survival or immune-mediated regression of metastasis outside the radiation field, a phenomenon known as abscopal effect. However, toxicities due to repeated systematic administration of IA have been shown to be a major obstacle in clinical trials. To minimize the toxicities and prime a more potent immune response, Ngwa et al have proposed that inert radiotherapy biomaterials such as fiducials could be upgraded to multifunctional ones loaded with IA for in situ delivery directly into the tumor sub-volume at no additional inconvenience to patients...
December 21, 2016: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/27909639/factors-associated-with-the-use-of-radiation-therapy-in-patients-with-stage-iii-non-small-cell-lung-cancer-in-alberta-canada-a-population-based-study
#7
Hong-Wei Liu, Marc Kerba, Gerald Lim, Zsolt Gabos, Ivo A Olivotto, Anil Abraham Joy, Wilson Roa, Zoann Nugent, Harold Lau
BACKGROUND: Cancer care in Alberta, Canada is publicly funded and provides patients with access to health care facilities and providers. The distribution of patients and health services across Alberta presents challenges to the delivery of cancer care, especially radiation therapy. In this study, we examined the association between patient and health system factors, the use of radiation therapy and survival outcomes in patients with stage III non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The provincial cancer registry was used to identify all patients who presented with clinical stage III NSCLC, diagnosed from 2005 to 2007, in Alberta...
October 27, 2016: Curēus
https://www.readbyqxmd.com/read/27908621/radiotherapy-with-curative-intent-in-patients-with-early-stage-medically-inoperable-non-small-cell-lung-cancer-a-systematic-review
#8
REVIEW
Conrad B Falkson, Emily T Vella, Edward Yu, Medhat El-Mallah, Robert Mackenzie, Peter M Ellis, Yee C Ung
Patients with early-stage non-small-cell lung cancer (NSCLC) who are unable to undergo surgery can be offered radiation therapy (RT). Previously, conventional RT was offered; however, newer techniques such as stereotactic body RT (SBRT) have become available. The objective of the present systematic review was to investigate the effectiveness of RT with curative intent in patients with early-stage medically inoperable NSCLC. MEDLINE, EMBASE, and the Cochrane Library were searched for studies comparing stereotactic RT with curative intent compared with observation or other types of RT for early-stage, medically inoperable, NSCLC...
October 27, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27908252/the-combination-of-new-immunotherapy-and-radiotherapy-a-new-potential-treatment-for-locally-advanced-non-small-cell-lung-cancer
#9
Paola Claudia Sacco, Paolo Maione, Cesare Guida, Cesare Gridelli
Lung cancer is the main reason of cancer death worldwide. About 30% of non-small-cell lung cancer (NSCLC) cases are diagnosed with locally advanced disease (stage III). This is a mixed population including patients who have far more extensive and bulky disease than others. Management of these patients continue to be a challenge; frequently, patients have both local recurrence and distant metastases in this stage and the prognosis is very poor with a 5-year overall survival estimated between 3% and 7% for inoperable disease...
December 1, 2016: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/27904449/tracheal-cancer-treatment-results-prognostic-factors-and-incidence-of-other-neoplasms
#10
Aleksandra Napieralska, Leszek Miszczyk, Sławomir Blamek
BACKGROUND: Tracheal cancers (TC) are rare and treatment results that are reported are typically not satisfactory. The purpose of this research was assessment of the results of treatment of TC patients, identification of potential additional surgery candidates, evaluation of prognostic factors, and assessment of the occurrence of other malignancies. PATIENTS AND METHODS: The Regional Cancer Database and the Hospital Database were searched for patients with tracheal neoplasms...
December 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27900105/palliative-sequential-chemoradiotherapy-for-pulmonary-sulcus-tumor-a-case-report
#11
Miki Kikuchi, Toshihiro Ohtani, Tomohiro Tamura, Hiroaki Satoh
Pulmonary sulcus tumors are occasionally encountered in non-small-cell lung cancer (NSCLC) patients. If the patients have a good clinical condition, concurrent chemoradiotherapy is indicated. However, palliative chemotherapy and chemoradiotherapy for patients exhibiting a poor overall condition have not been reported to date. We herein report the case of a 54-year-old female patient with a pulmonary sulcus tumor, who had a poor performance status. The patient received sequential chemoradiotherapy, with no severe complications...
November 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27900051/sensitization-strategies-in-lung-cancer
#12
Xiao-Ying Zhang, Peiying Zhang
The commonly used treatment avenues employed by cancer physicians include surgery, radiotherapy (RT) and chemotherapy in addition to rapid developmental and confirmatory studies on the efficacy of targeted therapies. However, the success rate in these commonly used treatments remains relatively low due to associated side effects, such as normal cell targeting/toxicity and resistance. In addition, investigators are continuing their efforts to enhance the efficacy of RT and chemotherapy to prevent associated side effects and improve the survival rate of the affected patient in order to increase patient survival...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27900019/the-relationship-between-tumor-volume-changes-and-serial-plasma-osteopontin-detection-during-radical-radiotherapy-of-non-small-cell-lung-cancer
#13
Christian Ostheimer, Franziska Schweyer, Thomas Reese, Matthias Bache, Dirk Vordermark
The prognostic quality of increased osteopontin (OPN) plasma levels has been demonstrated for the chemotherapy and surgery of lung cancer. There is also evidence in the literature that tumor volume impacts prognosis in definitive radiotherapy (RT) of (lung) cancer. We previously demonstrated that elevated plasma levels of OPN before, and increasing OPN plasma levels after RT significantly correlate with survival and outcome after curative-intent RT of non-small-cell lung cancer (NSCLC). Tumor volume was also associated with prognosis...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27898750/-curative-radiotherapy-of-early-stage-lung-cancer-using-respiratory-motion-compensation
#14
András Szilágyi, Tamás Pócza, Csaba Polgár, Tibor Major, András Bajcsay, József Lövey
In this paper we present our early experience with a method for the management of respiratory motion in radiotherapy for early-stage lung cancer. Forty-six patients were irradiated with a total dose of 60 Gy. Tumor response on control CT, survival, local and distant progression as well as early and late side effects were registered. Complete and partial remission, stable and progressive disease was 17 (37.0%), 15 (32.6%), 11 (23.9%) and 3 (6.5%). Isolated local recurrence and distant metastasis appeared in 4 (8...
November 29, 2016: Magyar Onkologia
https://www.readbyqxmd.com/read/27897060/potential-for-adaptive-dose-escalation-in-radiotherapy-for-patients-with-locally-advanced-non-small-cell-lung-cancer-in-a-low-mid-income-setting
#15
Sushma Agrawal, Sunil Kumar, Anil Kumar Maurya
OBJECTIVE: To evaluate the effect of tumour volume regression on adaptive treatment planning, reduction in doses to organs at risk (OAR) and dose escalation. METHODS: 20 patients undergoing radical chemoradiotherapy were imaged in fifth week of radiotherapy (CT_45) to evaluate differences in tumour volume regression between concurrent (CONC) and sequential chemoradiotherapy (SEQ). Replanning was done on CT_45 in those with >20% regression (n=10) and evaluated for change in target coverage indices (coverage index [CI], external volume index [EI]) and doses to OAR [mean lung dose, V20 and V5 of whole and ipsilateral lung (MLDWL, V20WL, V5WL, MLDIL, V20IL, V5IL), mean esophagus dose, V50 esophagus and maximum spinal cord doses]...
November 29, 2016: British Journal of Radiology
https://www.readbyqxmd.com/read/27896639/seom-clinical-guideline-for-bone-metastases-from-solid-tumours-2016
#16
C Grávalos, C Rodríguez, A Sabino, M Á Seguí, J A Virizuela, A Carmona, J Cassinello, D Isla, C Jara, M Martín
Bone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. Bone metastases can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compression, need of bone irradiation or need of bone surgery, and hypercalcaemia. Patients with bone metastases experience pain, functional impairment and have a negative impact on their quality of life. Several imaging techniques are available for diagnosis of this disease...
November 28, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27895920/pd1-pd-l1-inhibition-as-a-potential-radiosensitizer-in-head-and-neck-squamous-cell-carcinoma-a-case-report
#17
Misako Nagasaka, Mark Zaki, Harold Kim, S Naweed Raza, George Yoo, Ho-Sheng Lin, Ammar Sukari
BACKGROUND: Immunotherapy targeting the checkpoint PD1 (programmed cell death protein 1) or PDL1 (programmed death ligand 1) has led to advances in the treatment of melanoma and non-small cell lung cancer (NSCLC). The use of such therapies has also been introduced into the treatment of other malignancies, including head and neck cancer. The combined effects of checkpoint inhibitors and anti-PD1(L1) antibodies and radiation therapy have not yet been sufficiently investigated. CASE PRESENTATION: We report a case of locally relapsed non-resectable oral cavity squamous cell carcinoma, with excellent local control after pembrolizumab (MK3475) followed by radiotherapy...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27895753/drug-resistance-analysis-of-gefitinib-targeted-therapy-in-non-small-cell-lung-cancer
#18
Shuliang Liu, Hongji Yang, Xingping Ge, Lingfei Su, Aifeng Zhang, Liang Liang
The aim of the study was to examine the drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer (NSCLC). In total, 156 NSCLC patients without surgical treatment were selected, including 117 cases of adenocarcinoma (75%), to receive single gefitinib 0.25 g/day or combined with platinum chemotherapy. Computed tomography was used to evaluate tumor growth for the response and non-response groups. The chemotherapy regimen was changed or combined with radiotherapy in the non-response group...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27895491/comparison-of-internal-target-volumes-defined-on-3-dimensional-4-dimensonal-and-cone-beam-ct-images-of-non-small-cell-lung-cancer
#19
Fengxiang Li, Jianbin Li, Zhifang Ma, Yingjie Zhang, Jun Xing, Huanpeng Qi, Dongping Shang
PURPOSE: The purpose of this study was to compare the positional and volumetric differences of internal target volumes defined on three-dimensional computed tomography (3DCT), four-dimensional CT (4DCT), and cone-beam CT (CBCT) images of non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: Thirty-one patients with NSCLC sequentially underwent 3DCT and 4DCT simulation scans of the thorax during free breathing. The first CBCT was performed and registered to the planning CT using the bony anatomy registration during radiotherapy...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27894335/everolimus-and-exemestane-in-long-survival-hormone-receptor-positive-male-breast-cancer-case-report
#20
Z Ballatore, M Pistelli, N Battelli, A Pagliacci, M De Lisa, R Berardi, S Cascinu
BACKGROUND: Male breast cancer is a rare event, accounting for approximately 1% of all breast carcinomas. Although men with breast cancer had poorer survival when compared with women, data on prognosis principally derive from retrospective studies and from extrapolation of female breast cancer series. We reported the case of a very long survival patient. CASE PRESENTATION: A caucasian 42-year-old man underwent radical mastectomy with axillary dissection for breast cancer in 1993...
November 28, 2016: BMC Research Notes
keyword
keyword
30701
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"